1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol Chemical Properties

Boiling point:

580.2±50.0 °C(Predicted)

Density 

1.328±0.06 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

Soluble in DMSO

pka

13.68±0.70(Predicted)

1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol Usage And Synthesis

Description

Emiglitate (BAY O 1248), another deoxynojirimycin analogue is characterized by at least five-fold higher inhibitory potency than acarbose and additionally shows a long-lasting inhibitory effect. In animal studies emiglitate was still active up to 17 h after a single oral administration due to its pharmacokinetic behavior (formation of an active metabolite). Both miglitol and emiglitate differ in their pharmacokinetic behavior from acarbose, which is poorly absorbed (1 – 2 %). The deoxynojirimycin derivatives are structurally related to monosaccharides and will be absorbed in the jejunum.

1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol (80879-63-6)Related Product Information

• Repaglinide
• Miglitol
• N-METHYL-1-DEOXYNOJIRIMYCIN
• 4-[2-(1-Piperidinyl)ethoxy]benzaldehyde
• 1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol
• 1-Deoxynojirimycin
• N,N-BIS(2-HYDROXYETHYL)ISOPROPANOLAMINE
• DIETHANOL PROPANOLAMINE
• 4-[2-(DIMETHYLAMINO)ETHOXY]BENZALDEHYDE
• 4-(2-(DIETHYLAMINO)-ETHOXY)-BENZALDEHYDE
• 4-HYDROXY-1-PIPERIDINEETHANOL 96
• 1,5-DIDEOXY-1,5-IMINO-XYLITOL
• trans-3,4-Dihydroxypiperidine
• 4-(2-piperdinylethoxy)benzoic acid hydrochloride
• [4-[2-(DIMETHYLAMINO)ETHOXY]PHENYL]METHANOL
• 4-(2-AMINOETHOXY)BENZOIC ACID